Shares of Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) dropped 1.3% during mid-day trading on Tuesday . The company traded as low as $3.07 and last traded at $3.14, with a volume of 158,634 shares traded. The stock had previously closed at $3.18.

Separately, Maxim Group raised their price target on Adamis Pharmaceuticals Corp. from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, March 29th.

The stock’s market cap is $42.89 million. The firm’s 50-day moving average is $4.27 and its 200-day moving average is $5.69.

In other news, SVP David J. Marguglio sold 4,860 shares of the company’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $10.00, for a total value of $48,600.00. Following the completion of the sale, the senior vice president now owns 106,227 shares in the company, valued at $1,062,270. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP David J. Marguglio sold 4,000 shares of the company’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $8.08, for a total value of $32,320.00. Following the completion of the sale, the senior vice president now owns 102,227 shares of the company’s stock, valued at approximately $825,994.16. The disclosure for this sale can be found here.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.